BioFactura and Rani Therapeutics enter into agreement relating to proposed ustekinumab biosimilar

Sep 9, 2021

BioFactura announced it has reached an agreement with Rani Therapeutics to assess BFI-751 (proposed ustekinumab biosimilar) in combination with the RaniPill® platform. The RaniPill® capsule is intended to replace subcutaneous or IV injection of biologics with oral dosing.

Print Page Mail Article